ZA954941B - Monomeric insulin analog formulations - Google Patents

Monomeric insulin analog formulations

Info

Publication number
ZA954941B
ZA954941B ZA954941A ZA954941A ZA954941B ZA 954941 B ZA954941 B ZA 954941B ZA 954941 A ZA954941 A ZA 954941A ZA 954941 A ZA954941 A ZA 954941A ZA 954941 B ZA954941 B ZA 954941B
Authority
ZA
South Africa
Prior art keywords
insulin analog
monomeric insulin
analog formulations
formulations
monomeric
Prior art date
Application number
ZA954941A
Other languages
English (en)
Inventor
Michael Rosario De Felippis
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22989963&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA954941(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ZA954941B publication Critical patent/ZA954941B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA954941A 1994-06-16 1995-06-14 Monomeric insulin analog formulations ZA954941B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/260,633 US5461031A (en) 1994-06-16 1994-06-16 Monomeric insulin analog formulations

Publications (1)

Publication Number Publication Date
ZA954941B true ZA954941B (en) 1996-12-17

Family

ID=22989963

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA954941A ZA954941B (en) 1994-06-16 1995-06-14 Monomeric insulin analog formulations

Country Status (37)

Country Link
US (3) US5461031A (cs)
JP (1) JP3812962B2 (cs)
KR (1) KR100386038B1 (cs)
CN (1) CN1145641C (cs)
AT (1) AT408611B (cs)
BE (1) BE1009409A5 (cs)
BR (1) BR9502797A (cs)
CA (1) CA2151564C (cs)
CH (2) CH693019A5 (cs)
CO (1) CO4410204A1 (cs)
CZ (1) CZ294556B6 (cs)
DE (1) DE19521753B4 (cs)
DK (1) DK176213B1 (cs)
ES (1) ES2091728B1 (cs)
FI (1) FI118208B (cs)
FR (1) FR2721215B1 (cs)
GB (1) GB2290294B (cs)
GR (1) GR1002494B (cs)
HU (1) HU218943B (cs)
IE (1) IE68852B1 (cs)
IL (1) IL114153A (cs)
IT (1) IT1276722B1 (cs)
LU (1) LU88627A1 (cs)
MY (1) MY116831A (cs)
NL (2) NL1000565C2 (cs)
NO (1) NO320808B1 (cs)
NZ (1) NZ272360A (cs)
PE (1) PE34496A1 (cs)
PL (1) PL183284B1 (cs)
PT (1) PT101723B (cs)
RO (1) RO115124B1 (cs)
SE (1) SE509295C2 (cs)
SI (1) SI9500199A (cs)
TW (1) TW347334B (cs)
UA (1) UA34468C2 (cs)
YU (1) YU39795A (cs)
ZA (1) ZA954941B (cs)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1607086A1 (en) * 1993-01-29 2005-12-21 Aradigm Corporation Method of use of monomeric insulin as a means for improving the reproducibility of inhaled insulin
US6024090A (en) * 1993-01-29 2000-02-15 Aradigm Corporation Method of treating a diabetic patient by aerosolized administration of insulin lispro
US5888477A (en) * 1993-01-29 1999-03-30 Aradigm Corporation Use of monomeric insulin as a means for improving the bioavailability of inhaled insulin
US6131567A (en) * 1993-01-29 2000-10-17 Aradigm Corporation Method of use of monomeric insulin as a means for improving the reproducibility of inhaled insulin
DK72793D0 (da) * 1993-06-21 1993-06-21 Novo Nordisk As Nyt produkt
US5461031A (en) * 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5547929A (en) * 1994-09-12 1996-08-20 Eli Lilly And Company Insulin analog formulations
AR002976A1 (es) * 1995-03-31 1998-05-27 Lilly Co Eli Formulaciones farmaceuticas parenterales de efecto prolongado de insulina; cristales de dichos analogos aplicables en dichas formulaciones yprocedimiento de las formulaciones mencionadas
US6274549B1 (en) * 1995-06-30 2001-08-14 Novo Nordisk A/S Treatment of type 1 diabetes
JP4404380B2 (ja) * 1996-06-20 2010-01-27 ノボ ノルディスク アクティーゼルスカブ ＮａＣｌ含有インスリン製剤
US5898067A (en) * 1997-02-07 1999-04-27 Novo Nordisk A/S Crystallization of proteins
JP3343129B2 (ja) * 1997-02-07 2002-11-11 ノボ ノルディスク アクティーゼルスカブ タンパク質の結晶化
PE79099A1 (es) * 1997-06-13 1999-08-24 Lilly Co Eli Formulaciones de insulina estables
SI0884053T1 (en) * 1997-06-13 2003-02-28 Eli Lilly And Company Stable insulin formulations
ID24890A (id) * 1997-10-24 2000-08-31 Lilly Co Eli Komposisi-komposisi insulin yang tidak dapat larut
CO4970787A1 (es) 1997-12-23 2000-11-07 Lilly Co Eli Composiciones insolubles de insulina y derivados de insulina que controlan la glucosa sanguinea
US20010007853A1 (en) * 1998-01-08 2001-07-12 Dimarchi Richard Dennis Method for administering monomeric insulin analogs
US20040214747A1 (en) * 1999-01-06 2004-10-28 Dimarchi Richard Dennis Method for administering monomeric insulin
US6624141B1 (en) 1999-03-17 2003-09-23 The Regents Of The University Of Michigan Protamine fragment compositions and methods of use
US7169889B1 (en) * 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
US7678364B2 (en) 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
US20030054015A1 (en) * 2000-12-25 2003-03-20 Shinichiro Haze Sympathetic-activating perfume composition
DK1358209T3 (da) * 2001-02-09 2007-05-07 Genentech Inc Krystallisering af IGF-1
US6867183B2 (en) 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7060675B2 (en) 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US6858580B2 (en) * 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6713452B2 (en) 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6835802B2 (en) * 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US6828305B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7713932B2 (en) 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
JP2005508895A (ja) * 2001-08-28 2005-04-07 イーライ・リリー・アンド・カンパニー Ｇｌｐ−１および基礎インスリンの予備混合物
US7166571B2 (en) 2001-09-07 2007-01-23 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7030082B2 (en) * 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
US7196059B2 (en) 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
US6913903B2 (en) 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7312192B2 (en) 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US20030068361A1 (en) * 2001-10-09 2003-04-10 Rimona Margalit Liposome-encapsulated insulin formulations
MXPA04003569A (es) * 2001-10-19 2004-07-23 Lilly Co Eli Mezclas bifasicas de glp-1 e insulina.
WO2003053460A1 (en) * 2001-12-19 2003-07-03 Eli Lilly And Company Crystalline compositions for controlling blood glucose
WO2003105768A2 (en) * 2002-06-13 2003-12-24 Nobex Corporation Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
US20060258561A1 (en) * 2003-03-13 2006-11-16 Novo Nordisk A/S Novel NPH insulin preparations
MXPA05013723A (es) 2003-06-17 2006-03-13 Sembiosys Genetics Inc Metodos para loa produccion de insulina en plantas.
US20050054818A1 (en) * 2003-07-02 2005-03-10 Brader Mark Laurence Crystalline compositions for controlling blood glucose
US20060241019A1 (en) * 2003-07-25 2006-10-26 Bridon Dominique P Long lasting insulin derivatives and methods thereof
JP4601627B2 (ja) * 2004-01-16 2010-12-22 バイオデル， インコーポレイテッド 舌下薬物送達デバイス
JP5022213B2 (ja) * 2004-03-12 2012-09-12 バイオデル， インコーポレイテッド 迅速に作用する薬物送達組成物
US20080090753A1 (en) * 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
US20080085298A1 (en) * 2004-03-12 2008-04-10 Biodel, Inc. Rapid Mucosal Gel or Film Insulin Compositions
US20080096800A1 (en) * 2004-03-12 2008-04-24 Biodel, Inc. Rapid mucosal gel or film insulin compositions
PL2626368T3 (pl) 2004-07-19 2017-06-30 Biocon Limited Koniugaty insulina-oligomer, ich formulacje i zastosowania
KR20070085227A (ko) * 2004-08-09 2007-08-27 앨리오스 바이오파마 인크. 합성 초글리코실화, 프로테아제 저항성 폴리펩티드 변이체,경구 제제 및 이를 이용한 방법
US7597884B2 (en) * 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
EP2918286B1 (en) 2004-10-05 2020-03-18 Novo Nordisk A/S Pharmaceutical preparation containing insulin in crystalline as well as in solubilized form
WO2006053906A1 (en) 2004-11-22 2006-05-26 Novo Nordisk A/S Soluble, stable insulin-containing formulations with a protamine salt
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
US7713929B2 (en) * 2006-04-12 2010-05-11 Biodel Inc. Rapid acting and long acting insulin combination formulations
US8084420B2 (en) * 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
CN100371346C (zh) * 2005-12-14 2008-02-27 浙江大学 人工合成胰岛素模拟肽及其应用
WO2007096431A1 (en) * 2006-02-27 2007-08-30 Novo Nordisk A/S Insulin derivatives
US8927015B2 (en) 2006-04-12 2015-01-06 Emisphere Technologies, Inc. Formulations for delivering insulin
CA2649109A1 (en) * 2006-04-12 2007-10-25 Biodel, Inc. Rapid acting and long acting insulin combination formulations
CN101062948B (zh) * 2006-04-29 2010-05-12 上海生物泰生命科学研究有限公司 单体速效胰岛素及其制法和用途
WO2008124522A2 (en) * 2007-04-04 2008-10-16 Biodel, Inc. Amylin formulations
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
ES2664822T3 (es) 2007-10-16 2018-04-23 Biocon Limited Una composición farmacéutica sólida administrable por vía oral y un proceso de la misma
CA2711561A1 (en) * 2008-01-04 2009-07-16 Biodel, Inc. Insulin formulations for insulin release as a function of tissue glucose levels
ES2477552T3 (es) 2008-09-08 2014-07-17 The Board Of Trustees Of The Leland Stanford Junior University Moduladores de la actividad de la aldehidodeshidrogenasa y métodos de uso de los mismos
WO2010062308A1 (en) 2008-10-28 2010-06-03 The Board Of Trustees Of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase and methods of use thereof
US8940690B2 (en) 2009-01-28 2015-01-27 National Institutes Of Health (Nih) Synthetic conjugates and uses thereof
CA2750262C (en) * 2009-01-28 2016-08-09 Smartcells, Inc. Conjugate based systems for controlled drug delivery
BRPI1008415A2 (pt) 2009-02-12 2018-02-27 Proyecto De Biomedicina Cima S.L. uso de cardiotrofina-1 para o tratamento de doenças metabólicas
US9060927B2 (en) * 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
CA2754950A1 (en) 2009-03-20 2010-09-23 Smartcells, Inc. Terminally-functionalized conjugates and uses thereof
HUP0900482A2 (en) * 2009-08-03 2011-03-28 Cera Med Kft Pharmaceutical formulation for oral administration
AU2011282988A1 (en) 2010-07-28 2013-01-31 Smartcells, Inc. Recombinantly expressed insulin polypeptides and uses thereof
EP2643009A4 (en) * 2010-11-24 2015-04-01 Durect Corp COMPOSITION FOR THE RELEASE OF BIODEGRADABLE ACTIVE SUBSTANCES
PH12013501495A1 (en) 2011-01-20 2013-09-16 Zealand Pharma As Combination of acylated glucagon analogues with insulin analogues
WO2012149106A1 (en) 2011-04-29 2012-11-01 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
JP6735561B2 (ja) 2012-12-03 2020-08-05 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｏ−グリコシル化カルボキシ末端部分（ｃｔｐ）ペプチド系のインスリンおよびインスリン類似体
JP6410790B2 (ja) 2013-03-14 2018-10-24 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー ミトコンドリアアルデヒドデヒドロゲナーゼ−２調節因子およびその使用方法
US9427475B2 (en) 2013-10-04 2016-08-30 Merck Sharp & Dohme Corp. Glucose-responsive insulin conjugates
JP6564369B2 (ja) 2013-12-09 2019-08-21 デュレクト コーポレイション 薬学的活性剤複合体、ポリマー複合体、ならびにこれらを伴う組成物及び方法
CN105899191B (zh) * 2014-01-09 2020-06-16 赛诺菲 胰岛素类似物和/或胰岛素衍生物的稳定化不含甘油的药物制剂
EP3094343A4 (en) * 2014-01-13 2017-10-18 Thermalin Diabetes, LLC Rapid action insulin formulations and pharmaceutical delivery systems
AR099569A1 (es) 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
EP3006045B3 (en) 2014-10-07 2021-03-17 Cyprumed GmbH Pharmaceutical formulations for the oral delivery of peptide or protein drugs
WO2017163159A1 (en) 2016-03-21 2017-09-28 Wockhardt Limited Biphasic pharmaceutical composition of insulin human
RS65380B1 (sr) 2017-08-24 2024-04-30 Novo Nordisk As Glp-1 kompozicije i njihova upotreba
US11110063B2 (en) 2017-08-25 2021-09-07 MAIA Pharmaceuticals, Inc. Storage stable sincalide formulations
US11820805B2 (en) 2017-12-18 2023-11-21 Merck Sharp & Dohme Llc Conjugate based systems for controlled insulin delivery
EP3740212A4 (en) 2017-12-18 2021-10-27 Merck Sharp & Dohme Corp. CONJUGATE-BASED SYSTEMS FOR CONTROLLED INSULIN DELIVERY
CN110063932A (zh) * 2019-04-12 2019-07-30 浙江大学 一种多肽蛋白类药物的缓释组合物制剂及其制备方法
IL294520A (en) 2020-02-18 2022-09-01 Novo Nordisk As Pharmaceutical formulations
CR20220555A (es) 2020-03-31 2023-01-23 Protomer Tech Inc Conjugados para reactividad selectiva a dioles vecinales
KR20230110505A (ko) 2020-11-19 2023-07-24 프로토머 테크놀로지스 인크. 방향족 붕소-함유 화합물 및 인슐린 유사체
IL317049A (en) 2022-05-18 2025-01-01 Protomer Tech Inc Aromatic boron-containing compounds and related insulin analogs

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2538018A (en) * 1944-04-04 1951-01-16 Nordisk Insulinlab Crystalline product of insulin and alkaline protein and process of making it
US2801953A (en) * 1952-02-28 1957-08-06 Hoechst Ag Process of preparing crystallized insulin preparations
US2849370A (en) * 1953-06-04 1958-08-26 Novo Terapeutisk Labortorium A Injectable insulin preparations with protracted effect and process of producing same
US3060093A (en) * 1957-07-18 1962-10-23 Nordisk Insulinlab Slowly acting insulin preparation in crystalline form and method of preparation
US3868358A (en) * 1971-04-30 1975-02-25 Lilly Co Eli Protamine-insulin product
DE3326473A1 (de) * 1983-07-22 1985-01-31 Hoechst Ag, 6230 Frankfurt Pharmazeutisches mittel zur behandlung des diabetes mellitus
DE3327709A1 (de) * 1983-07-29 1985-02-07 Hoechst Ag, 6230 Frankfurt Insulin-derivat-kristallsuspensionen, verfahren zu deren herstellung und deren verwendung
DK119785D0 (da) * 1985-03-15 1985-03-15 Nordisk Gentofte Insulinpraeparat
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
JP2606915B2 (ja) * 1987-02-25 1997-05-07 ノボ ノルディスク アクティーゼルスカブ 新規インシュリン誘導体
DE3717370A1 (de) * 1987-05-22 1988-12-01 Hoechst Ag Mischkristalle aus insulin und insulinderivaten, verfahren zur herstellung dieser mischkristalle, diese mischkristalle enthaltende pharmazeutische mittel und ihre verwendung zur behandlung von diabetes mellitus
EP0425482B1 (en) * 1988-07-20 1993-08-18 Novo Nordisk A/S Human insulin analogs and preparations containing them
HUT56857A (en) * 1988-12-23 1991-10-28 Novo Nordisk As Human insulin analogues
US5514646A (en) * 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
NZ232375A (en) * 1989-02-09 1992-04-28 Lilly Co Eli Insulin analogues modified at b29
JP2837956B2 (ja) * 1993-06-21 1998-12-16 ノボ ノルディスク アクティーゼルスカブ Ａｓｐ▲上Ｂ２８▼インスリン結晶
DK72793D0 (da) * 1993-06-21 1993-06-21 Novo Nordisk As Nyt produkt
US5461031A (en) * 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5474978A (en) * 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations

Also Published As

Publication number Publication date
IT1276722B1 (it) 1997-11-03
YU39795A (sh) 1998-05-15
JPH083064A (ja) 1996-01-09
NL1004643A1 (nl) 1996-12-17
NL1000565C2 (nl) 1996-12-03
BR9502797A (pt) 1996-03-12
US5650486A (en) 1997-07-22
IE68852B1 (en) 1996-07-24
CZ154395A3 (en) 1996-02-14
ATA101795A (de) 2001-06-15
HUT71908A (en) 1996-02-28
PT101723B (pt) 1997-02-28
KR960000923A (ko) 1996-01-25
CO4410204A1 (es) 1997-01-09
FI952932A0 (fi) 1995-06-14
PL309100A1 (en) 1995-12-27
ES2091728A1 (es) 1996-11-01
NL1004643C2 (nl) 1997-02-12
DE19521753B4 (de) 2009-07-23
ITMI951277A0 (it) 1995-06-14
CH693019A5 (de) 2003-01-31
FR2721215A1 (fr) 1995-12-22
IL114153A (en) 2000-09-28
US5747642A (en) 1998-05-05
NO320808B1 (no) 2006-01-30
CA2151564C (en) 2003-02-11
BE1009409A5 (fr) 1997-03-04
LU88627A1 (fr) 1996-02-01
GB2290294B (en) 1999-03-17
PT101723A (pt) 1995-12-29
SE9502168D0 (sv) 1995-06-14
CN1145641C (zh) 2004-04-14
DE19521753A1 (de) 1995-12-21
ES2091728B1 (es) 1998-02-01
RO115124B1 (ro) 1999-11-30
JP3812962B2 (ja) 2006-08-23
DK67695A (da) 1995-12-17
PE34496A1 (es) 1996-10-01
FR2721215B1 (fr) 1997-08-14
CA2151564A1 (en) 1995-12-17
FI118208B (fi) 2007-08-31
GB9512105D0 (en) 1995-08-09
SE509295C2 (sv) 1999-01-11
CN1116629A (zh) 1996-02-14
GR1002494B (el) 1996-12-12
TW347334B (en) 1998-12-11
NZ272360A (en) 1997-02-24
CH689934A5 (de) 2000-02-15
NL1000565A1 (nl) 1995-12-18
IL114153A0 (en) 1995-10-31
US5461031A (en) 1995-10-24
DK176213B1 (da) 2007-02-12
KR100386038B1 (ko) 2003-08-27
CZ294556B6 (cs) 2005-02-16
SI9500199A (en) 1996-02-29
IE950435A1 (en) 1995-12-27
HU9501717D0 (en) 1995-08-28
SE9502168L (sv) 1995-12-17
MY116831A (en) 2004-04-30
AT408611B (de) 2002-01-25
HU218943B (hu) 2001-01-29
NO952356D0 (no) 1995-06-14
PL183284B1 (pl) 2002-06-28
GB2290294A (en) 1995-12-20
FI952932L (fi) 1995-12-17
UA34468C2 (uk) 2001-03-15
ITMI951277A1 (it) 1996-12-14
NO952356L (no) 1995-12-18

Similar Documents

Publication Publication Date Title
GB2290294B (en) Monomeric insulin analog formulations
IL117696A (en) Monomeric insulin analog formulations
GB2291427B (en) Insulin analog formulations
IL133348A0 (en) Stable insulin formulations
SI0884053T1 (en) Stable insulin formulations
GB9323399D0 (en) Pharmaceutical formulations
GB9311030D0 (en) Pharmaceutical formulations
GB2327424B (en) Monomeric insulin analog formulations
AU2168295A (en) Monomeric insulin analog formulations
AU738101C (en) Monomeric insulin analog formulations
EG26644A (en) Preparations of monoclonal insulin analogs
AU731636C (en) Insulin analog formulations
AU694501C (en) Insulin analog formulations
HK1015138B (en) Insulin analog formulations
GB9304799D0 (en) Pharmaceutical formulations
GB9315119D0 (en) Pharmaceutical formulations
GB9312344D0 (en) Pharmaceutical formulations
GB9302908D0 (en) Pharmaceutical formulations
GB9314443D0 (en) Pharmaceutical formulations
GB9301250D0 (en) Pharmaceutical formulations
GB9321676D0 (en) Pharmaceutical formulations
GB9304800D0 (en) Pharmaceutical formulations
GB9306144D0 (en) Formulations